ClinicalTrials.gg
RecruitingNCT07674173PEARLUpdated Jun 29, 2026

Post-market European & Asian Registry to Evaluate the Minos™ Stent-Graft and Delivery System in Abdominal Aortic Aneurysm Treatment

An observational study in Endovascular Repair of Infrarenal Abdominal Aortic Aneurysm Using Endovascular Stent Graft, sponsored by Shanghai MicroPort Endovascular MedTech(Group)Co., Ltd. Recruiting at 16 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-29.

Sponsored by Shanghai MicroPort Endovascular MedTech(Group)Co., Ltd (part of MicroPort Scientific Corporation) · Observational

How we know

From the registry’s dates

  • Started Mar 2023; still recruiting 3 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Aortic Aneurysm, Abdominal with a site in China — 7 open to participants now, 9 under way, none of them phase 3. Aortic Aneurysm, Abdominal · China.

Started
2023
with 1 other
Observational
9 of 17
5 open now
Registered
16th of 17
by date

Among the 17 studies in Aortic Aneurysm, Abdominal with a site in China, this one is one of 2 that started in 2023, is one of 9 observational ones, and was the 16th registered.

Aortic Aneurysm, Abdominal

467 studies on the registry are indexed under Aortic Aneurysm, Abdominal; 99 are open to participants now.

Browse Aortic Aneurysm, Abdominal studies →

Open to participants now

7 of the 17 studies in Aortic Aneurysm, Abdominal with a site in China are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 66 Aortic Aneurysm, Abdominal studies recruiting now, 52 (79%) set no upper age limit and 3 (5%) stop at 75 or younger; 2 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Aortic Aneurysm, Abdominal with a site in China, or all of them as a file.
02

Study summary

The Minos™ Abdominal Aortic Stent-Graft and Delivery System is a medical device designed to treat abdominal aortic aneurysms using a minimally invasive procedure. The device is placed inside the aorta through blood vessels, usually accessed through small incisions in the groin. The goal of this observational study is to collect short-, medium- to long-term safety and performance data of the Minos™ stent-graft in everyday medical practice (real-world settings). The aim is to study about 200 patients worldwide and at least 30 patients in European hospitals.

03

Conditions studied

  • Endovascular Repair of Infrarenal Abdominal Aortic Aneurysm Using Endovascular Stent Graft

Keywords

  • Minos™ Abdominal Aortic Stent-Graft and Delivery System
  • EVAR
  • abdominal aortic aneurysm (AAA)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Chinese and European subjects suffering abdominal aortic aneurysm with a proximal neck length ≥15mm.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of infrarenal abdominal aortic aneurysm
  • Plan to treat with Minos Abdominal Aortic Stent-Graft and Delivery System
  • Voluntary participation and completion of Form, with willingness to participate in follow-up to 5 years post-procedure

Exclusion criteria

Exclusion Criteria:

  • Subjects in whom use of the Minos™ Abdominal Aortic Stent-Graft and Delivery System is , as follows:
  • Severe stenosis or calcification near the aneurysm, leading to difficulty in achieving apposition of vessel wall and stent graft.
  • Difficult access due to severe stenosis or tortuosity in the iliac artery or femoral artery.
  • Subjects with ruptured aneurysm or acute aneurysm.
  • Subjects with an infectious aneurysm.
  • Those who are allergic to contrast agents or unable to tolerate contrast agents due to renal insufficiency.
  • Patients with severe coagulation disorder and/or high risk of postoperative hemorrhage.
  • Aneurysmal neck angulation greater than 60°.
  • Patients with blood supply to vital organs originating from the aneurysmal sac.
  • Patients with other comorbidities and whose does not exceed one year.
  • Subjects with connective tissue diseases, such as Marfan syndrome.
  • Minors and pregnant women.
  • Subjects who are allergic to nitinol.
  • Subjects who are considered not suitable for treatment with stent graft.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes

Groups and cohorts

  • PEARL participants

    All subjects to be treated with Minos™ Abdominal Aortic Stent-Graft and Delivery System who meet the criteria for inclusion in the PEARL study and voluntarily consent to participate.

    Device: Implantation with Minos Stent graft

Interventions

  • DeviceImplantation with Minos Stent graft

    Treatment of subjects diagnosed with abdominal aortic aneurysm using the low-profile Minos Abdominal Aortic Stent-Graft and Delivery System. Follow up as per institutional standard of care.

06

What researchers measure

Primary outcomes

  1. Technical success rate at 12 months

    Technical success at 12 months is defined as accurate positioning of stent graft, normal stent shape, no distortion, bending, stenosis and occlusion, and no accidental coverage of internal iliac artery or visceral artery, the absence of aneurysm rupture, continuous type I and III endoleaks after operation, aneurysm enlargement (aneurysm diameter increased by more than 5mm), secondary intervention due to endoleak, stent occlusion or migration, including open surgery and endovascular surgery. Expected secondary interventions will not be included in the analysis.

    Time frame: 12 months

Secondary outcomes

  1. Incidence of major adverse events at 30 days

    Time frame: 30 days

  2. Immediate technical success

    Immediate technical success is measured as successful introduction and withdrawal of stent graft and delivery system, with accurate positioning of stent graft, normal stent shape, no distortion, bending, stenosis and occlusion, and no accidental coverage of internal iliac artery or visceral artery.

    Time frame: within 24 hours post-implantation

  3. Incidence of successful aneurysm treatment at 2-5 years

    Successful aneurysm treatment during the follow-up period of 2-5 years is defined as accurate positioning of stent graft, normal stent shape, no distortion, bending, stenosis and occlusion, and no accidental coverage of internal iliac artery or visceral artery, the absence of aneurysm rupture, continuous type I and III endoleaks after operation, aneurysm enlargement (aneurysm diameter increased by more than 5mm), secondary intervention due to endoleak, stent occlusion or migration, including open surgery and endovascular surgery.

    Time frame: Years 2-5 post-implantation

  4. All-cause mortality up to 5 years post-procedure

    Time frame: From implantation to the end of follow up at 5 years

  5. Aortic aneurysm related mortality up to 5 years post-procedure

    Time frame: From implantation to the end of follow up at 5 years

  6. Secondary intervention rates up to 5 years post-procedure

    Secondary intervention rates up to 5 years after TEVAR are measured by tracking all subsequent open and endovascular procedures required to treat device-related or aortic complications. This includes Open surgery: performed at any time to address a failure of endovascular treatment due to failure of stent implantation or placement, complications or other clinical conditions, or after the initial success of endovascular treatment, and Secondary endovascular intervention: any intravascular surgical intervention performed to resolve complications such as endoleak, aneurysm expansion, stent occlusion, stent migration and stent defect after the implantation of Minos™ system.

    Time frame: From implantation to the end of follow up at 5 years

  7. Aneurysm diameter and variation in aneurysm diameter from 30 days to 5 years post-procedure

    Time frame: From 30 days post-implantation until end of follow up at 5 years

  8. Incidence of type I and type III endoleaks from 30 days to 5 years post-procedure

    Time frame: From 30 days post-implantation until end of follow up at 5 years

  9. Incidence rate of stent migration, fracture, stenosis, occlusion and distortion from 30 days to 5 years post-procedure

    Time frame: From 30 days post-implantation until end of follow up at 5 years

07

Study locations

14 of 16 sites recruiting
  • The Second Hospital of Lanzhou University
    Lanzhou, Gansu 730030, China
    Recruiting
    • Dong Zhou · Principal investigator
  • Meizhou People's Hospital
    Meizhou, Guangdong 514031, China
    Recruiting
    • Cunren Li · Principal investigator
  • The University of Hong Kong - Shenzhen Hospital
    Shenzhen, Guangdong 518053, China
    Recruiting
    • Minxin Wei · Principal investigator
  • Hunan Provincial People's Hospital
    Changsha, Hunan 410002, China
    Recruiting
    • Qing Wang · Principal investigator
  • Xiangtan Central Hospital
    Xiangtan, Hunan 411100, China
    Recruiting
    • Zhihong Fang · Principal investigator
  • Yueyang Central Hospital
    Yueyang, Hunan 414000, China
    Recruiting
    • Yi You · Principal investigator
  • Zibo Central Hospital
    Zibo, Shandong 255024, China
    Recruiting
    • Xinming Yu · Principal investigator
  • TEDA International Cardiovascular Hospital
    Binhai, Tianjin Municipality 300457, China
    Recruiting
    • Xuedong Li · Principal investigator
  • Kunming Yan'an Hospital
    Kunming, Yunnan 650051, China
    Recruiting
    • Huanjun Chen · Principal investigator
  • Fuwai Hospital
    Beijing, 100037, China
    Recruiting
    • Chang Shu · Principal investigator
  • Klinikverbund Allgäu
    Immenstadt im Allgäu, Allgäu 87439, Germany
    Recruiting
  • Universitätsklinikum Münster (UKM)
    Münster, 48149, Germany
    Recruiting
    • Jana Ebing · Contactvital@ukmuenster.de · 00492518351717
    • Alexander Oberhuber, Dr. med. univ. · Principal investigator
  • "G. Gennimatas" Thessaloniki General Hospital
    Thessaloniki, GR54635, Greece
    Recruiting
    • Georgios A. Pitoulias · Contactpitoulias@yahoo.com · 00302310992564
    • Georgios A. Pitoulias, MD, PhD · Principal investigator
  • Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (ASST Spedali Civili di Brescia)
    Brescia, 25123, Italy
    Not yet recruiting
  • Erasmus MC
    Rotterdam, 3015 GD, Netherlands
    Recruiting
  • Hospital Universitari de Girona Doctor Josep Trueta
    Girona, Catalonia 17007, Spain
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Oct 2028, 67 months after the start.

Of 91 observational studies under Aortic Aneurysm, Abdominal, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 83. This study's planned 67 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2026
First posted
Jun 29, 2026
StartActual
Mar 5, 2023
Primary completionEst.
Oct 22, 2028
CompletionEst.
Jan 22, 2033
Last update
Jun 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07674173
Responsible party
Sponsor
First posted
Jun 29, 2026
Start date
Mar 5, 2023
Primary completion
Oct 22, 2028 (estimated)
Completion
Jan 22, 2033 (estimated)
Last update
Jun 29, 2026

Study contacts

Maggie Shen, MD MSc
Contact
maggie.shen@endovastec-lm.com
00441235750800
Anne Woodman
Contact
anne.woodman@endovastec-lm.com
00441235750800
Jing Wang
study director · Shanghai MicroPort Endovascular MedTech(Group)Co., Ltd

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion